By a News Reporter-Staff News Editor at Life Science Weekly -- A new study on Proteins is now available. According to news reporting originating from Istanbul, Turkey, by NewsRx correspondents, research stated, "Targeted posttranscriptional gene silencing by RNA interference (RNAi) has garnered considerable interest as an attractive new class of drugs for several diseases, such as cancer. Chitosan and protamine are commonly used as a vehicle to deliver and protect small interfering RNA (siRNA), but the strong interaction still remains to be modulated for efficient siRNA uptake and silencing."
Our news editors obtained a quote from the research from Marmara University, "Therefore, in this study, ternary nanoplexes containing chitosan and protamine were designed to substantially enhance the siRNA efficiency. Binary and ternary nanoplexes were prepared at different the ratios of moles of the amine groups of cationic polymers to those of the phosphate ones of siRNA (N/P) ratios and characterized in terms of size, zeta potential, morphology and serum stability. The silencing efficiencies and cytotoxicities of prepared nanoplexes were evaluated by enzyme-linked immunosorbent assay (ELISA) (for human vascular endothelial growth factor; hVEGF) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively. The mean diameter of ternary nanoplexes ranged from 151 to 282nm, depending on the weight ratio between polymers and siRNA. The gene silencing effect after transfection with ternary nanoplexes (chitosan/siRNA/protamine 83%) was significantly higher than that with binary nanoplexes (chitosan/siRNA 71% and protamine/siRNA 74%). Ternary nanoplexes showed the highest cellular uptake ability when compared with binary nanoplexes. Ternary nanoplexes did not induce substantial cytotoxicity. Serum stability and the lack of cytotoxicity of the nanoplexes provided advantages over other gene silencing studies."
According to the news editors, the research concluded: "These results suggest ternary nanoplexes have the potential to be an effective siRNA carrier to study the gene silencing effect."
For more information on this research see: The Development of Ternary Nanoplexes for Efficient Small Interfering RNA Delivery. Biological & Pharmaceutical Bulletin, 2013;36(12):1907-1914. Biological & Pharmaceutical Bulletin can be contacted at: Pharmaceutical Soc Japan, 2-12-15Shibuya, Shibuya-Ku, Tokyo, 150-0002, Japan (see also Proteins).
The news editors report that additional information may be obtained by contacting E. Salva, Marmara Univ, Fac Pharm, Dept. of Pharmaceut Biotechnol, TR-34668 Istanbul, Turkey. Additional authors for this research include S.O. Turan and J. Akbuga.
Keywords for this news article include: Turkey, Eurasia, Istanbul, Protamines, Nucleoproteins, Nuclear Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC